CuraSen’s SPARK

How neurodegenerative disease play CuraSen plans to deploy its $54.5M series A

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years.

New Leaf Venture

Read the full 324 word article

User Sign In